Deletion of all or part of chromosome 9q is the most common genetic alteration in all stages and grades of bladder cancer. DBCCR1 (deleted in bladder cancer chromosome region candidate 1) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer. Although no mutations of DBCCR1 have been detected in bladder tumours, expression of DBCCR1 is silenced by promoter hypermethylation in 50% of bladder cancer cell lines analysed. Here we sought to provide functional evidence to authenticate DBCCR1 as a tumour suppressor using gene-transfer methods. Exogenous expression of DBCCR1 protein or an HA epitopetagged fusion protein, HA-DBCCR1 in NIH3T3 cells and human bladder tumour cell lines resulted in suppression of proliferation. Cell cycle analyses in NIH3T3 cells revealed that DBCCR1-mediated growth inhibition was due to an increase in the number of cells in the G 1 phase of the cell cycle. The levels of apoptosis were not altered. These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer. Oncogene (2001) 20, 2956 ± 2964.
Introduction
Transitional cell carcinoma (TCC) of the urothelium of the bladder, ureter and renal pelvis is amongst the commonest of human cancers with 12 000 new cases in the UK and 54 000 in the US per annum (Parker et al., 1997; Oce for National Statistics, 1996) . In TCC, loss of heterozygosity (LOH) on chromosome 9q and/or 9p is one of the most frequent genetic alterations (450%) and is detected consistently in all stages and grades of tumours (Cairns et al., 1993; Dalbagni et al., 1993; Olumi et al., 1990; Wu et al., 1991) indicating that this may represent an early event in tumour development. This observation indicates that there are likely to be important tumour suppressor genes for TCC on 9p and/or 9q and one of these genes might represent à gatekeeper' for urothelial cells (Kinzler and Vogelstein, 1996) . Detailed LOH studies of chromosome 9q in TCC have indicated that there are several candidate tumour suppressor loci (Cairns et al., 1993; Dalbagni et al., 1993; Olumi et al., 1990; Simoneau et al., 1999) , one of which is at 9q32-33 (Habuchi et al., 1995 (Habuchi et al., , 1997 Nishiyama et al., 1999b) . The putative tumour suppressor gene in this region has been designated DBC1 (deleted in bladder cancer 1). Using YAC and PAC contigs spanning the DBC1 region, we identi®ed a candidate tumour suppressor gene, DBCCR1 (deleted in bladder cancer chromosomal region candidate 1) (Habuchi et al., 1998; Nishiyama et al., 1999a) . DBCCR1 encodes a putative protein of 761 amino acids with a predicted mass of 88.7 kDa. Mutation analyses of the coding region and Southern blot analyses detected neither somatic mutations nor gross genetic alterations in primary TCC. Although transcripts of DBCCR1 are expressed in multiple normal human tissues including urothelium, its expression is suppressed by hypermethylation of the 5' CpG island in 50% of bladder cancer cell lines investigated, suggesting that DBCCR1 may be the target gene (Habuchi et al., 1998) . The function of DBCCR1 remains elusive since it has no signi®cant homology with known amino acid sequences and as yet no predicted structure. To address its candidacy as a tumour suppressor gene, we have used gene transfer methods to investigate the eects of DBCCR1 protein expression on cell proliferation and apoptosis.
Results

Polymorphisms of DBCCR1
Previous studies identi®ed three silent polymorphisms in the coding sequence of DBCCR1 (Habuchi et al., 1997) ; T 1036 C (Ser -4Ser), C 2044 A (Ile -4Ile), and T 2642 C (Leu -4Leu). Further sequencing of cDNA clones, human DNAs from the blood of normal volunteers and TCC tumour patients resulted in the identi®cation of four further single base changes; T 1459 A (Arg -4Ser), G 1491 A (Arg -4His), A 1727 G (Thr -4Ala), T 1759 C (Cys -4Cys). Analysis of these changes in samples of normal volunteers and cDNA clones revealed that three of the changes were common polymorphisms; T 1459 A (33% of samples), A 1727 G (25%), and T 1759 C (60%). The fourth single base change (G 1491 A) was found only in cDNA clone ICRFp507K12270 (Habuchi et al., 1997) but not in 23 normal human genomic samples and six cDNA clones analysed. For functional analyses, we used a cDNA sequence containing none of these polymorphisms (wildtype) and a sequence containing G 1491 A and A 1727 G (polymorphic).
Molecular weight of DBCCR1 protein
Based on the predicted protein sequence of DBCCR1, the calculated mass was 88.7 kDa (Habuchi et al., 1997) . To verify this, DBCCR1 cDNA was fused with an HA epitope tag at the 5'-end, transfected into NIH3T3 cells and analysed by Western blotting using an anti-HA antibody. The relative mobility of HA-DBCCR1 was shown to be approximately 100 kDa (Figure 1a, left) . Since this was larger than the predicted size, DBCCR1 was fused with green¯uor-escent protein (GFP) at the 3'-end, transfected and examined by Western blotting with an anti-GFP antibody. This detected DBCCR1-GFP at 130 kDa and GFP alone at 30 kDa (Figure 1a , right), con®rm-ing the relative mobility of DBCCR1 to be 100 kDa.
Subcellular localization of DBCCR1 protein
The subcellular localization of DBCCR1 was investigated using transient transfectants of NIH3T3 expressing HA-DBCCR1. Immuno¯uorescence studies showed that DBCCR1 protein was localized primarily in the cytoplasm (Figure 1b,c) . This observation was supported by analysis of NIH3T3 cells expressing a DBCCR1-GFP fusion in which the protein was also expressed only in the cytoplasm (Figure 1d ,e).
Inhibition of NIH3T3 cell proliferation by DBCCR1
The eect of DBCCR1 on cell proliferation was investigated using NIH3T3 cells stably transfected with either epitope tagged HA-DBCCR1, non-tagged DBCCR1, antisense-DBCCR1, HA-DBCCR1-P (contains both G1491A and A1727G sequence variants), or vector alone (control). Cells were maintained in culture for 10 days following transfection before cell number and colony morphology were examined. Comparison of HA-DBCCR1 transfected cells with those transfected with vector alone (control) indicated that the majority of HA-DBCCR1 transfectant colonies were smaller in size than controls and showed altered morphology (Figure 2a, b) . In addition, the number of viable cells in HA-DBCCR1 transfectant populations were about fourfold lower than those in control cultures ( Figure 2c ). Similarly, transfection of nontagged DBCCR1 and DBCCR1-P resulted in growth suppression compared to controls (Figure 2c ). Conversely, transfection with antisense-DBCCR1 did not result in growth suppression (Figure 2c ). Large colonies that were obtained following HA-DBCCR1 transfection were morphologically similar to controls but when picked and expanded, did not show expression of the HA-DBCCR1 fusion protein by Western blotting. Smaller colonies were also picked but less than half of these could be expanded and only half of those which were expanded showed HA-DBCCR1 expression (data not shown). DBCCR1-induced growth suppression of NIH3T3 cells was also demonstrated using a transient cotransfection system. In this assay, an expression construct containing GFP targeted to the endoplasmic reticulum (ER-GFP) was co-transfected with either DBCCR1 or HA-DBCCR1 in order to monitor transfected cells by¯ow cytometry. The system was optimized using LacZ constructs in conjunction with ER-GFP. In this system 590% of ER-GFP positive cells also expressed LacZ (data not shown). Analysis of DBCCR1/HA-DBCCR1 transfectants demonstrated no dierence in cell number compared to controls 24 h after transfection, but a dramatic decrease in the proportion of ER-GFP positive cells was observed at 4 days post-transfection compared to controls (Figure 2d) .
Negative regulation of G 1 /S transition by DBCCR1
To examine whether the reduction in proliferation was due to an eect on the cell cycle, the DNA content of transfected cells was analysed using propidium iodide (PI) staining and¯ow cytometric analysis. Co-transfection of ER-GFP with the DBCCR1 constructs was used to provide a¯uorescent selection marker for successfully transfected cells and analysis was performed 72 h post-transfection. Transfection of vector alone did not aect cell cycle distribution. In contrast, transfection of HA-DBCCR1 resulted in an increase in the G 1 population of cells and a decrease in the number of cells in both S and G 2 /M phases of the cell cycle ( Figure 3a) . A more precise assessment of the eects of DBCCR1 on the cell cycle was achieved by ®rst synchronizing cells in a particular phase of the cycle. Serum-starvation of NIH3T3 cells for 24 h resulted in an accumulation of cells in G 1 . Reintroduction of serum resulted in entry into S phase 16 h later ( Figure 3b , GFP negative fraction). HA-DBCCR1 and control transfectants were analysed 16 h after release from serum-starvation-induced G 1 arrest. In both conditions, GFP negative cells showed almost the same cell cycle distribution. In contrast, HA-DBCCR1 transfectants were retained in G 1 (mean of three experiments; 83.8+5.53%), whereas control transfectants demonstrated a`normal' cell cycle distribution (mean of three experiments; 46.2+7.79%; Figure 3b ).
Cell cycle synchronization using the microtubulestabilizing agent nocodazole causes cells to arrest in G 2 /M phase. Treatment of NIH3T3 cells with nocodazole for 24 h resulted in 590% of the cells accumulating in G 2 /M. Following nocodazole treatment, cells transfected with either vector alone or antisense-DBCCR1 accumulated in G 2 /M (mean of three experiments; 78.8+1.19% and 76.0+2.92%, respectively). In contrast, cells transfected with either HA-DBCCR1 or DBCCR1 were retained in G 1 even after 24 h of nocodazole treatment (mean of three experiments; 58.1+3.35% and 58.1+2.76%, respectively) (Figure 3c ). These results reinforced the hypothesis that growth suppression by DBCCR1 is due to the retention of cells in G 1 .
Effect of DBCCR1 on apoptosis
Since several tumour suppressor genes induce apoptosis in concert with an induction of cell cycle arrest, the eect of DBCCR1 on the level of apoptosis was analysed. The level of apoptosis following DBCCR1 transfection was measured using the TUNEL assay and compared to the level of apoptosis induced by two dierent agents, etoposide and nuclease treatment. Successfully transfected cells were identi®ed by ER-GFP expression and analysed by¯ow cytometry. The incidence of apoptosis in both HA-DBCCR1 and DBCCR1 expressing cells was not signi®cantly dierent to that observed in cells transfected with either antisense-DBCCR1 or vector alone (Figure 4 ). In contrast, both nuclease and etoposide treatments resulted in an induction of apoptosis (Figure 4) . Therefore, DBCCR1 does not appear to directly perturb apoptosis when exogenously expressed in NIH3T3 cells.
Effect of DBCCR1 in human bladder tumour cells
The bladder tumour cell lines EJ and 5637 have been shown previously to have lost one entire chromosome 9 homologue (Williamson et al., 1995) . Neither shows expression of DBCCR1 and this is associated with DNA methylation of the retained allele (Habuchi et al., 1998) . The eect of DBCCR1 expression was investigated following transfection with HA-DBCCR1 or control vector. These human cell lines show a lower transfection frequency than NIH3T3 which did not permit repetition of the¯ow cytometric analysis of transient transfectants described above for NIH3T3. Instead, stable transfectants were selected following transfection.
In EJ, fewer stable transfectant colonies were obtained following transfection with HA-DBCCR1 than with control vector (Figure 5a ). Cell counts of mass populations of transfected cells after 6 days of selection in G418 showed a decrease in cell number of approximately 30% compared with controls but there was no signi®cant morphological dierence between DBCCR1 transfectants and controls. Attempts to pick and expand transfectant colonies were slightly less successful for DBCCR1 transfectants than controls (17/21 for DBCCR1 vs 19/21 for HA vector) but only four of the 17 DBCCR1 transfected clones showed expression of the HA-DBCCR1 fusion protein by Western blotting (data not shown). No signi®cant dierence in the rate of proliferation was found for stable DBCCR1-expressing clones (data not shown).
The eects of DBCCR1 in the cell line 5637 were more profound than in EJ. After 9 days of selection in G418, small colonies could be identi®ed in DBCCR1 transfected cultures but these were much smaller than controls. The majority of these small colonies subsequently died and by 14 days after transfection only a very few colonies survived (Figure 5b ). Expansion of these colonies has proved dicult and to date no further experiments have been possible on such clones.
Discussion
This study provides functional evidence that the candidate tumour suppressor gene DBCCR1 identi®ed within the DBC1 region of deletion at 9q32-33 in bladder cancer has growth-suppressing activity. Although the precise cellular function of the gene remains to be elucidated, we have shown that its antiproliferative eect is mediated via modulation of the G 1 checkpoint.
Genomic alterations of chromosome 9, particularly deletions, are the most common genetic events in bladder cancer and several potential tumour suppressor loci have been localized on 9p and 9q. Molecular genetic and cytogenetic analyses indicate that a locus or loci on 9q are relevant at an early stage in the development of super®cial papillary tumours. For example, in studies where multiple synchronous or metachronous papillary tumours from the same Oncogene Functional analysis of DBCCR1 H Nishiyama et al individual have been analysed, LOH of 9q has been the most frequent and consistent ®nding, as expected for an early event in tumour development. The presumed precursor lesion for papillary TCC is urothelial hyperplasia and a recent study has identi®ed loss of chromosome 9 by FISH analysis in both histologically normal and hyperplastic biopsies from patients with a history of bladder cancer (Hartmann et al., 1999) . We postulate that the tumour suppressor(s) located in the DBC1 region may have critical involvement early in bladder tumorigenesis since all the tumours identi®ed with either small interstitial hemizygous or homozygous deletion in the DBC1 region have been low grade super®cial tumours (pTa, G1) (8, 9). DBCCR1 is the only candidate gene so far identi®ed within the relatively gene poor critical region of deletion at 9q32-33 (Habuchi et al., 1997 (Habuchi et al., , 1998 . This gene was shown previously to be silenced by methylation in 50% of bladder cancer cell lines (Habuchi et al., 1998) and to be homozygously deleted in a primary tumour (Nishiyama et al., 1999b) but small intragenic tumour-speci®c mutations have not been identi®ed. The non-conformity of this gene to the Knudson twohit mechanism for tumour suppressor gene inactivation by mutation (Knudson, 1971 ) may indicate either that DBCCR1 is not the critical target gene or that it represents one of the rapidly growing class of suppressor genes that do not show inactivation by two mutational events. For example, the second allele may be inactivated predominantly by epigenetic means such as methylation, as previously observed (Habuchi et al., 1998) . Alternatively, haplo-insuciency may provide an adequate selective advantage at the cellular level. For instance, if the levels of a tumour suppressor protein and its cellular target are ®nely balanced such that perturbation of the levels of either one results in an alteration in a growth control pathway, then haploid levels of a tumour suppressor may confer an altered phenotype as demonstrated for p27 KIP1 and PTEN (Di Cristofano et al., 1998; Fero et al., 1998) .
In the absence of mutation of the gene except by homozygous deletion, authentication as a tumour suppressor relies largely on functional analysis. NIH3T3 cells were used for initial transfections and cell cycle analysis because of the ease with which they can be transfected. We have shown that exogenous expression of DBCCR1 resulted in the suppression of proliferation of NIH3T3 cells and that this was due to the accumulation of cells in the G 1 phase of the cell cycle. Synchronization of cells either by serum starvation (G 1 ) or nocodazole treatment (G 2 /M) provided further support for G 1 -retention by the DBCCR1 protein. Interestingly, DBCCR1 did not cause a complete G 1 cell cycle arrest, since a small proportion of the population expressing the protein (*20%) were located in other phases of the cycle. This may be due to lower expression levels of DBCCR1 protein in these cells, the presence of a sub-population of cells which were`resistant' to the eects of DBCCR1 or may indicate that DBCCR1 causes a slower G 1 -transition rather than G 1 -arrest. In addition to the short term eects of DBCCR1 on the cell cycle, the observed diculty in expanding DBCCR1-transfected clones and the failure of many of those that were expanded to express the protein, revealed a long-term DBCCR1-associated growth inhibition compatible with G 1 -retention.
Since NIH3T3 cells express mRNA from the mouse DBCCR1 homologue (J Gill, 2001, unpublished results) we wished to relate our observations more directly to human bladder tumorigenesis. We therefore introduced the gene into two bladder tumour cell lines which show loss of one allele of the gene and methylation induced silencing of the retained allele. The eects in these cells were striking and included a signi®cant inhibition of proliferation. Future experiments with inducible expression constructs should allow a more detailed examination of the precise eects of DBCCR1 expression on the phenotype of these cells. It will be important to examine the eects of lower levels of expression of the gene, for example under control of its own promoter and to study the eects of modulation of gene expression in normal urothelial cells.
Western blotting and immuno¯uorescence studies demonstrated that DBCCR1 is a 100 kDa protein localized in the cytoplasm. This sub-cellular localization of DBCCR1 suggests an indirect eect on the G 1 cell cycle machinery. Tumour suppressor genes have been demonstrated to regulate cell proliferation by perturbing both sides of the survival balance, resulting in a decrease in cell survival and an increase in cell death. For example, p53 induces both cell cycle arrest and apoptosis in a number of dierent cell types, the outcome being dependent on cell type and microenvironment (Sionov and Haupt, 1999) . In contrast, p16 INK4A functions to regulate G 1 cyclin-dependent kinase activity and thus proliferation (Roussel, 1999 ), but does not directly mediate cell death. Our data indicates that DBCCR1 mediates G 1 cell cycle progression, but does not aect apoptosis either directly or as a result of prolonged G 1 retention (424 h). This suggests that DBCCR1 is more likely to impinge on a pathway upstream of a cell cyclè gatekeeper' such as p16
INK4A than upstream of a genomic`gatekeeper' and`caretaker' such as p53. One hypothesis is that it may act upstream of the G 1 checkpoint in a manner analogous to survival factors such as epidermal growth factor or negative factors such as transforming growth factor-beta 1 (TGFb 1 ). For example, the TGFb 1 pathway is known to cause a G 1 cell cycle arrest in many cell types by both upregulating G 1 -cell cycle inhibitory molecules, p15
, and down-regulating levels of the cyclin dependent kinase 4 (CDK4) (Ewen et al., 1993; Ravitz and Wenner, 1997; Roussel, 1999) . Thus, DBCCR1 may act as a`checkpoint sentry', halting proliferation in order for other molecules to examine genomic ®delity, neoplastic potential and ultimately determine cell fate. Since DBCCR1 demonstrates no signi®cant homology to any known amino acid sequence, (Habuchi et al., 1998) , an exact role for this protein remains to be elucidated. Further analysis of these pathways and more ecient gene transfer methods such as retroviral or adenoviral-mediated gene transfer will be helpful in future functional studies.
Assessment of the frequency of alterations of expression of DBCCR1 in primary tumours has proved dicult and it is not yet clear how many primary tumours with loss of one allele of DBCCR1 by LOH have lost expression from the other allele via hypermethylation of the promoter. We have shown that 52% of bladder tumours have aberrant methylation of a region of exon 1 of DBCCR1 containing 20 CpG dinucleotides (Habuchi et al., 2001) . The frequency of methylation at certain speci®c CpGs however, is relatively low (Salem et al., 2000) and we have not found an absolute relationship of methylation with mRNA expression in cell lines (J Coulter and M Knowles, 2001, unpublished observations). Methylation levels therefore do not provide an adequate surrogate for expression that can be used in tumour DNA samples. A satisfactory antibody to the DBCCR1 protein has not yet been generated and levels of expression of the mRNA are too low to be detected by in situ hybridization. The possibility remains therefore, that loss of activity of one allele is sucient for phenotypic alteration of urothelial cells. In vitro studies and the generation of DBCCR1-null mice may help to establish the possible eects of DBCCR1 haploinsuciency and con®rm its role as a tumour suppressor.
Materials and methods
Cell culture and transfection
NIH3T3 cells were maintained in Dulbecco's modi®cation of Eagle's medium with 2 mM L-glutamine and 10% foetal calf serum. The human bladder tumour cell lines EJ and 5637 were maintained in Dulbecco's modi®cation of Eagle's medium and RPMI 1640 respectively, both supplemented with 2 mM L-glutamine and 10% foetal calf serum. Transfections were performed using Lipofectamine Plus Reagent (Life Technologies, Paisley, UK) following the manufacturer's protocol. Brie¯y, cells were seeded at 4610 5 (NIH3T3), 3610 5 (EJ) or 5610 5 (5637) per 6 cm diameter dish 24 h prior to transfection with 2 mg of an expression construct. For co-transfection experiments, DBCCR1 expression constructs and control plasmid (pBABE/GEM) were mixed in a 9 : 1 ratio and a total of 2 mg of plasmid DNA was used per dish. Stable transfectants were selected in G418 (Life Technologies) at 800 mg/ml (3T3) or 400 mg/ml (EJ and 5637).
Cloning of the DBCCR1 gene and construction of plasmids for transfection pGreen Lantern-2 was purchased from Life Technologies. pCDNA3.1/myc-His and pCDNA3.1/lacZ/myc-His were purchased from Invitrogen (Groningen, Netherlands). pBABE/GEM, which expresses a green¯uorescence protein targeted to the endoplasmic reticulum (ER-GFP) (Pestov et al., 1999) , was a gift from Dr D Pestov (Department of Genetics, University of Illinois). pMKIT/HA was modi®ed from pMKIT/neo to contain a haemagglutinin (HA) tag downstream of the SRa promotor (13). pMKIT/neo and pMKIT/HA were gifts from Dr K Maruyama (Tokyo Medical and Dental University School of Medicine) and Dr J Fujita (University of Kyoto).
The coding sequence of DBCCR1 was obtained from EST ICRFp507k12270 (Higashitsuji et al., 2000) or p507k12270N, which was modi®ed from ICRFp507K12270 to change A1491 to G and G1727 to A by PCR-based mutagenesis. To generate DBCCR1-expression constructs, PCR ampli®cation of the DBCCR1 coding region was performed using primers DBC-F (5'-ACGCGTCGACATGAACTGGAGGTTTGTT) and DBC-R (5'-ATAAGAATGCGGCCGCTTAGCA-GAGTTTGGCTGT). PCR was for 25 cycles of 948C for 1 min, 558C for 1 min and 728C for 1 min using AmpliTaq Gold DNA polymerase (Perkin Elmer, Warrington, UK). PCR products generated from ICRFp507K12270 or p507K12270N were ligated into the SalI ± NotI site of pMKIT/HA to generate DBCCR1 tagged with HA at the N-terminus, termed pMKIT/HA-DBCCR1P or pMKIT/HA-DBCCR1, respectively. To generate a non-tagged DBCCR1 expression construct (pMKIT/DBCCR1), the NaeI ± NotI fragment of DBCCR1 was ligated into the EcoRV ± NotI site of pMKIT/neo. To generate an antisense construct, the NaeI ± EcoRV fragment of DBCCR1 was ligated into the EcoRI ± EcoRV site of pMKIT/HA in the anti-sense orientation. To generate a DBCCR1-GFP fusion protein, DBCCR1 (nucleotides 380 ± 2701) was fused with GFP (nucleotides 10 ± 747, from pGreen Lantern-2) and ligated into pCDNA3.1. All constructs were sequenced to eliminate PCR-generated artefacts.
Western blot analysis
Western blot analysis was performed as previously described (Nishiyama et al., 1997) . Brie¯y, cells were transfected as indicated above and harvested 48 h after transfection by lysis in RIPA buer [150 mM NaCl, 50 mM TrisHCl pH 7.4, 5 mM EDTA, 1% Triton X-100, 1% Nadeoxycholate, 0.1% SDS, 1 mM phenylmethylsuphonyl uoride (PMSF), 50 mM NaF, and both proteinase inhibitor (16) and protein phosphatase inhibitor cocktails (16) (Sigma, Dorset, UK)]. Protein concentrations were determined using the BioRad protein assay (BioRad, Hemel Hempstead, UK). Ten mg of protein was loaded per lane of 8% SDS polyacrylamide gels (SDS ± PAGE). Protein was blotted onto nitrocellulose membranes (Hybond   TM   ECL   TM , Amersham, Buckinghamshire, UK) using a semi-dry blotting system (BioRad). Equal protein loading on the membrane was veri®ed using Ponceau S staining (Sigma). Non-speci®c binding of antibodies to the membrane was blocked using 5% dried milk powder (BioRad) in PBS containing 0.2% Tween 20. The membranes were probed using either anti-HA monoclonal antibody (12CA5; (Niman et al., 1983) ) or anti-GFP monoclonal antibody (3E1; a kind gift from Dr S Geley, ICRF, UK), localized using anti-mouse secondary antibody conjugated to horseradish peroxidase (Dako, UK) and detected using enhanced chemiluminescence reagents and Hyper®lm ECL (Amersham).
Immunoprecipitation
Cells were transfected with either pCDNA3.1/DBCCR1-GFP or pCDNA3.1/GFP as detailed above and maintained in culture for 48 h. Cells (1610 6 ) were lysed in immunoprecipitation (IP) sample buer (50 mM TrisHCl pH 7.4, containing 5 mM EDTA, 0.1% Triton X, 100 mM NaCl, 1 mM PMSF, 10 mM NaF, 1 mM DTT, 10% glycerol and both protease inhibitor (16) and protein phosphatase inhibitor cocktails (16)). Lysates were incubated with anti-GFP antibody (3E1), cross-linked with protein G-sepharose and the complex precipitated. The pellet was solubilized in RIPA buer with 66loading dye and analysed by Western blotting, as detailed above.
Immunocytochemistry
Immunocytochemistry was performed as previously described (Nishiyama et al., 1997) . Brie¯y, transfected cells were reseeded on multiwell slides (Hendley, Essex, Essex, UK) at 24 h post-transfection. Following a further 24 h in culture, cells were ®xed in methanol:acetone (1 : 1) and labelled with a rabbit anti-HA antibody (Y11; Santa-Cruz Biotech., CA, USA). Primary antibody was localized using goat anti-rabbit Ig F(ab') 2 conjugated to FITC (Southern Biotechnology Associates Inc, Birmingham, USA). Cells were counterstained with Hoechst 33258 (Molecular Probes, Eugene, USA) and viewed by¯uorescence microscopy.
Measurement of cell proliferation
Transfected cells were seeded at 1610 5 cells / 6 cm diameter dish at 24 h post-transfection and cultured for 10 days in growth medium containing G418 (800 mg/ml) for selection of stably transfected clones. Cell counts were performed using a haemocytometer and colonies were stained in situ with methylene blue.
Cell cycle analysis
Transfected cells were re-seeded in 10 cm diameter dishes at 24 h post-transfection and harvested for cell cycle analysis at 72 h post-transfection. Cells were synchronized in the cell cycle by either serum starvation (G 1 arrest), or nocodazole treatment (G 2 arrest). For serum starvation experiments, cells were maintained in 10% serum for 24 h, serum starved for 24 h and allowed to recover in medium with 10% serum for 16 h prior to harvesting and analysis. For nocodazoleinduced cell cycle arrest, cells were maintained in serum supplemented medium for 48 h post-transfection and then treated with nocodazole (40 ng/ml) for 16 h.
Synchronized cells were harvested, washed in PBS and ®xed in 70% ethanol at 48C. Cells were then incubated in PI (15 mM; Sigma) and RNase (4 mg/ml; Boehringer Mannheim, East Sussex, UK) for 30 min. Cell cycle distributions (PI, red uorescence) were analysed on a FACScan 1¯o w cytometer (Becton-Dickinson, Oxford, UK). Ten thousand events were acquired per sample and data were analysed using CellQuest software (Becton-Dickinson). For further analysis, the transfected cell population (GFP positive; green¯uorescence) were`gated' and their cell cycle distribution analysed.
Measurement of apoptosis
The eect of DBCCR1 on apoptosis was assessed by TUNEL assay using the FlowTACS in situ apoptosis detection kit (R&D systems, Abingdon, UK) following the manufacturer's protocol. Brie¯y, cells were co-transfected with expression constructs and pBABE/GEM as detailed above and maintained in culture for 72 h. Subsequently, adherent cells were trypsinized and combined with those harvested from the supernatant. The resulting cell pellet was ®xed in 4% paraformaldehyde and cells permeabilized by incubation in Cytopore for 30 min at room temperature. Permeabilized cells were labelled with biotin-conjugated dNTP using terminal deoxy-transferase, detected with phycoerythrin (PE)-conjugated avidin and analysed by¯ow cytometry (red uorescence). Transfected cells (GFP positive) were`gated' and analysed. Treatment of cells with either etoposide (100 mM; Sigma) for 48 h or incubation of ®xed cells with TACS nuclease (R&D Systems) for 10 min at 378C prior to analyses were used as positive apoptosis-inducing controls.
